Sequenom Announces Launch of SensiGene Fetal RHD Genotyping Test

Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of the SensiGene(TM) Fetal RHD Genotyping test by Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company’s first laboratory developed test powered by its SEQureDx(TM) technology.

Source: Sequenom